NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
Clinical Trials
6 trialsNCT06181734 2026-02-10
CONFIDHENCE
iOMEDICO AG
Completed
NCT03564821 2025-11-04
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT02989857 2024-08-20
ClarIDHy
Servier
Phase 3 Completed
NCT04176393 2023-02-13
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
CStone Pharmaceuticals
Phase 1 Completed